• Jiedu Xiaozheng Yin Drives M1 Macrophage Polarization via TL

  2026-07-09

  Liu et al. demonstrate that Jiedu Xiaozheng Yin (JXY) suppresses colitis-associated colorectal cancer (CAC) progression by promoting M1 macrophage polarization through the TLR4 pathway. This mechanistic insight advances our understanding of immune modulation in the tumor microenvironment and highlights avenues for integrating transcriptional coactivator disruption in cancer research.

• 2-Hydroxypropyl-β-cyclodextrin: Technical Use and Protocols

  2026-07-09

  2-Hydroxypropyl-β-cyclodextrin addresses the persistent challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those containing aromatic or phenyl groups—by forming inclusion complexes that significantly improve their aqueous solubility. It should be used as a drug formulation excipient or pharmaceutical solubility enhancer; applications outside validated solubility and formulation workflows are not currently supported by product documentation.

• S-Adenosylhomocysteine: Beyond Methylation—Precision in Neur

  2026-07-08

  Explore the pivotal roles of S-Adenosylhomocysteine in neuro-metabolic research, with a unique focus on functional assay design, cellular methylation potential, and recent advances linking methylation dynamics to neural differentiation. Uncover advanced protocol insights and how SAH shapes next-generation experimental models.

• WNT Signaling Drives Extrahepatic Bile Duct Proliferation Af

  2026-07-08

  Calder et al. (2025) demonstrate that WNT signaling, particularly via cholangiocyte-derived WNT ligands, is essential for the proliferative response of extrahepatic bile duct (EHBD) cells following obstructive injury in mice. Their integrative study provides mechanistic insight into WNT/β-catenin pathway involvement, revealing potential therapeutic targets for cholangiopathies characterized by biliary hyperproliferation.

• Dinaciclib Synthetic Lethality Targets VHL-Deficient Renal C

  2026-07-07

  A recent study demonstrates that the cyclin-dependent kinase inhibitor Dinaciclib induces synthetic lethality in VHL-deficient clear cell renal cell carcinoma (CC-RCC), selectively targeting tumor growth while sparing normal or VHL-reconstituted cells. This discovery highlights a promising therapeutic window for precision cancer treatment and informs the design of future research using selective enzymatic inhibitors.

• Applied Workflows with Recombinant Human FGF-19 Protein

  2026-07-07

  Recombinant Human FGF-19 (E.coli, Tag Free, Lyophilized) enables highly reproducible metabolic and signaling assays, offering unmatched purity and validated activity for precision research. This article details optimized experimental workflows, troubleshooting strategies, and key translational insights for leveraging FGF-19 protein in metabolic regulation studies.

• BGJ398 (NVP-BGJ398): Precision in FGFR-Driven Oncology Resea

  2026-07-06

  BGJ398 (NVP-BGJ398) is transforming FGFR-driven malignancies research by enabling targeted inhibition of FGFR1/2/3 in both cancer and developmental biology models. This guide offers actionable protocols, comparative advantages, and troubleshooting strategies to unlock the full potential of BGJ398 in experimental workflows.

• Recombinant Human FGF-19: Endocrine Metabolic Pathways & Adv

  2026-07-06

  Explore the unique endocrine mechanisms and advanced assay applications of Recombinant Human FGF-19 protein. This in-depth analysis reveals how precise ligand-receptor interactions and new mechanistic insights can transform metabolic and signaling research.

• 5-Azacytidine: Advanced Protocols for Epigenetic Modulation

  2026-07-05

  5-Azacytidine (5-AzaC) stands as a gold standard DNA demethylation agent, enabling precision in gene reactivation, apoptosis modeling, and resistance studies in multiple myeloma and leukemia. This guide translates cutting-edge findings into actionable workflows, troubleshooting, and comparative insights for researchers demanding reproducibility and mechanistic depth.

• Super-Enhancer-Driven KLF6 Regulation in hADSC Adipogenesis

  2026-07-04

  Nguyen et al. unveil how a super-enhancer near KLF6 orchestrates adipogenic differentiation in human adipose-derived stem cells (hADSCs). The study establishes a mechanistic link between super-enhancer activity, KLF6 induction, and the coordinated regulation of adipogenic and anti-adipogenic genes, offering new perspectives for metabolic and stem cell research.

• Valemetostat (DS-3201): Advancing Epigenetic Oncology

  2026-07-03

  This thought-leadership article explores the translational impact of Valemetostat (DS-3201), a selective dual EZH1/EZH2 inhibitor, within the evolving landscape of epigenetic cancer therapy. Through mechanistic insights, workflow guidance, and evidence-based clinical context, we empower translational researchers to bridge molecular understanding with patient-centric innovations in relapsed/refractory lymphoma.

• Glucocorticoid Receptor-Mediated CYP Suppression in Hippocam

  2026-07-03

  This study reveals that pregnenolone 16α-carbonitrile (PCN) suppresses hippocampal cytochrome P450 expression and mitigates phenytoin-induced neurotoxicity through a glucocorticoid receptor-dependent, PXR-independent pathway. These findings clarify nuclear receptor cross-talk in the brain and suggest new strategies to minimize neurological side effects of antiepileptic drugs.

• USP36-Snail1 Axis Drives Ribosome Biogenesis Under Ribotoxic

  2026-07-02

  This study reveals that USP36 stabilizes nucleolar Snail1, promoting ribosome biogenesis and solid tumor survival during ribotoxic stress. These findings clarify why ribosome-targeting agents like homoharringtonine are less effective in solid tumors and suggest combinatorial strategies to overcome resistance.

• Optimizing Cancer Epigenetics with EPZ-6438: EZH2 Inhibitor

  2026-07-02

  EPZ-6438, a potent EZH2 inhibitor from APExBIO, is redefining experimental strategies in epigenetic cancer research by enabling precise modulation of PRC2 activity. This guide unpacks optimized protocols, troubleshooting tactics, and translational insights for leveraging EPZ-6438 in HPV-associated and rare tumor models.

• CHIR-99021 (CT99021): Elevating Pluripotency and Directed Di

  2026-07-01

  CHIR-99021 (CT99021) stands out as a potent, selective GSK-3 inhibitor, enabling precise control of embryonic stem cell fate and robust neuronal differentiation. Here, we detail actionable workflows, highlight cross-domain findings, and deliver troubleshooting strategies to maximize experimental consistency in stem cell and neuron-based models.

11569 records 1/772 page Next 12345 下5页 Last page